2,473 Shares in Axsome Therapeutics, Inc. $AXSM Bought by Vise Technologies Inc.

Vise Technologies Inc. bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,473 shares of the company’s stock, valued at approximately $605,000.

Several other hedge funds have also bought and sold shares of AXSM. BlackRock Inc. purchased a new position in shares of Axsome Therapeutics during the 2nd quarter valued at about $759,695,000. Price T Rowe Associates Inc. MD grew its stake in shares of Axsome Therapeutics by 45.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,509,870 shares of the company’s stock valued at $275,763,000 after acquiring an additional 472,422 shares during the period. Wellington Management Group LLP increased its holdings in Axsome Therapeutics by 84.1% in the 3rd quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after acquiring an additional 609,516 shares in the last quarter. Invesco Ltd. increased its holdings in Axsome Therapeutics by 28.6% in the 4th quarter. Invesco Ltd. now owns 1,273,494 shares of the company’s stock worth $232,591,000 after acquiring an additional 282,937 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Axsome Therapeutics by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 1,010,249 shares of the company’s stock worth $184,544,000 after acquiring an additional 12,549 shares during the period. Institutional investors own 81.49% of the company’s stock.

Insiders Place Their Bets

In other news, Director Susan Mahony sold 300 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $237.21, for a total value of $71,163.00. Following the transaction, the director directly owned 1,129 shares in the company, valued at approximately $267,810.09. This represents a 20.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Mark Coleman sold 6,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $230.30, for a total transaction of $1,381,800.00. Following the completion of the transaction, the director owned 35,140 shares in the company, valued at $8,092,742. This represents a 14.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 200,766 shares of company stock worth $46,685,646. Insiders own 20.60% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AXSM. Deutsche Bank Aktiengesellschaft set a $280.00 price target on shares of Axsome Therapeutics in a report on Tuesday, May 5th. HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a research note on Monday. Truist Financial upgraded shares of Axsome Therapeutics to a “strong-buy” rating in a research note on Monday, June 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $272.00 target price on shares of Axsome Therapeutics in a report on Monday, May 4th. Finally, Robert W. Baird increased their price target on Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $267.60.

Axsome Therapeutics Price Performance

AXSM stock opened at $205.40 on Tuesday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43. The company’s fifty day moving average price is $231.17 and its 200-day moving average price is $206.29. Axsome Therapeutics, Inc. has a one year low of $112.90 and a one year high of $260.19. The company has a market capitalization of $10.76 billion, a PE ratio of -54.77 and a beta of 0.65.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.10). Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%.The firm had revenue of $218.38 million for the quarter, compared to analysts’ expectations of $221.11 million. On average, equities analysts anticipate that Axsome Therapeutics, Inc. will post -2.78 EPS for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.